BIOCRATES Goes Spain and Turkey
News May 10, 2012
BIOCRATES Life Sciences AG has announced that it has entered into a distribution and co-marketing agreement with MATERLAB in Spain and ONKOGEN Diagnostik in Turkey to bring its latest metabolomic product, SteroIDQ® Kit, to the markets of their respective countries.
SteroIDQ® kit, a CE-IVD ready-to-use kit, was successfully launched in Germany, Austria, and Switzerland earlier this year, and is the first of a new generation of steroid hormone kits, enabling the most comprehensive simultaneous analysis of a steroid panel yet available.
Analysis is based on tandem mass spectrometry (LC-MS/MS), which meets the most stringent quality control criteria for routine diagnostics and ensures extraordinary analytical sensitivity and selectivity.
Under the terms of the agreement, MATERLAB and ONKOGEN Diagnostik are granted rights for distribution and sale of all BIOCRATES products, its metabolomic research-use-only kits (AbsoluteIDQ® p150 Kit, AbsoluteIDQ® p180 Kit, MetaDisIDQ® Kit) as well as its novel CE-IVD SteroIDQ® Kit.
“We are happy to have found such competent and highly successful partners to support us in extending the BIOCRATES presence into the Spanish and Turkish market respectively.” says Elgar Schnegg, CEO of BIOCRATES.
Schnegg continued, “With the extensive distribution network of both MATERLAB and ONKOGEN Diagnostik, coupled with their drive and enthusiasm in bringing together cutting-edge products from prime biotech and microbiology manufacturers worldwide to serve laboratories across Spain and Turkey make them ideal partners in our endeavor of further expanding the European distribution network of BIOCRATES.”
“Mass Spectrometry represents the state-of-the art technology with a trend towards further expansion in the near future. It also meets most stringent quality criteria for routine diagnostics. We are pleased to start working with BIOCRATES which is highly experienced in the field of metabolomics and we are also happy to introduce this cutting edge technology to Turkish laboratories”, says Alper Söyler, General Manager of ONKOGEN.